Last reviewed · How we verify
statin, stable dose
At a glance
| Generic name | statin, stable dose |
|---|---|
| Sponsor | Genentech, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Assessing the Impact of Intensification of Lipid Lowering Therapy With Guidelines-based Evinacumab Administration on Coronary Plaque Volumes Measured by Coronary Computed Tomography Angiography (CCTA) in Patients With Homozygous Familial Hypercholesterolemia (HoFH)
- Efficacy and Safety of Pitavastatin/Ezetimibe After Switching From Statin Monotherapy to Pitavastatin/Ezetimibe in Patients With Hypercholesterolemia
- DNV001 Injection in Patients With Hypercholesterolemia (PHASE2)
- Changes in Plaque Characteristics After Short-term Statin Therapy as Assessed With Coronary CT (NA)
- Phase 2a Study to Assess CIVI 007 in Patients on a Background of Statin Therapy (PHASE2)
- A Dose-Finding Study in Japanese Patients to Evaluate the Effect of Obicetrapib as an Adjunct to Stable Statin Therapy. (PHASE2)
- Study of Evinacumab (REGN1500) in Participants With Persistent Hypercholesterolemia (PHASE2)
- Statin Monotherapy or Statins in Combination With Ezetimibe in Patients for Prevention of CVD
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- statin, stable dose CI brief — competitive landscape report
- statin, stable dose updates RSS · CI watch RSS
- Genentech, Inc. portfolio CI